Who is the CEO of Vectura Group plc?

Mr. William Downie is a business executive who currently serves as the CEO of Vectura Group plc.

What is the Revenue Growth of Vectura Group plc?

Revenue growth data for Vectura Group plc is currently unavailable.

What is Vectura Group plc operating Margin?

Vectura Group plc operating margin is 68.94% which shows how much profit VEC.L earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Vectura Group plc operate?

Vectura Group plc falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Vectura Group plc revenue growth?

Revenue growth data for Vectura Group plc is currently unavailable.

Vectura Group plc

VEC.L•LSE

HealthcareDrug Manufacturers - General

$164.80

$0.00(0.00%)

Vectura Group plc (VEC.L) Stock Overview

Explore Vectura Group plc’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for VEC.LStats details for VEC.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for VEC.LAnalyst Recommendations details for VEC.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Vectura Group Plc engages in the provision of pharmaceutical development. The company is headquartered in Chippenham, Wiltshire and currently employs 453 full-time employees. The firm's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

CEO

Mr. William Downie

Employees

502

Headquarters

Unit 1, Prospect West, Bumpers Way, Chippenham, WILTSHIRE

Founded

2004